AMENDMENTS TO THE CLAIMS

1. (currently amended) An antibody, comprising the V_H domain of the antibody produced by the hybridoma of ATCC deposit number CRL 8001, wherein the cysteine at position H100A of said V_H domain is substituted with a ~~polar amino acid~~ serine, wherein said position H100A is according to the Kabat numbering system, wherein said antibody comprises the amino acid sequence depicted by SEQ ID NO:2.

Claims 2-3 (cancelled).

4. (currently amended) A method for the production of the antibody according to claim 1, characterized by the steps of:

a) obtaining mRNA from freshly subcloned hybridoma cells of ATCC deposit number CRL 8001 and transcription into cDNA,

b) amplifying the cDNA coding for the variable domains of the light and heavy chains by means of PCR,

c) cloning of the cDNA obtained in b) into a vector adapted for site-specific mutagenesis,

d) introducing a mutation to the cDNA, wherein said mutation is the substitution of a cysteine with a ~~polar amino acid~~ serine at position H100A of the V_H domain according to the Kabat numbering system, and

e) inserting the mutated cDNA obtained in ~~c)~~ d) in an expression vector and expression in a suitable expression system.

5. (previously presented) The method according to claim 4, wherein the amplifying of step b) uses primers having the nucleotide sequences depicted by SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11 .

6. (previously presented) The method according to claim 4, wherein the vector used in step c) is pCR-Skript SK(+).

7. (previously presented) The method according to claim 4, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

Claim 8 (cancelled).

9. (previously presented)The method according to claim 4, wherein the expression takes place in XLl-Blue E. *coli* cells.

12. (previously presented)The method according to claim 5, wherein the vector used in step c) is pCR-Skript SK(+).

13. (previously presented)The method according to claim 5, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

14. (previously presented)The method according to claim 6, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

Claims 15-18 (cancelled).

19. (previously presented)The method according to claim 5, wherein the expression takes place in XLl-Blue E. *coli* cells.

20. (previously presented)The method according to claim 6, wherein the expression takes place in XLl-Blue E. *coli* cells.

21. (previously presented)The method according to claim 7, wherein the expression takes place in XLl-Blue E. *coli* cells.

Claim 22 (cancelled).

23. (previously presented)A peptide comprising the amino acid sequence depicted by SEQ ID NO:2.

24. (previously presented)An antibody comprising the peptide according to Claim 23.

25. (previously presented)A single-chain antibody comprising the peptide according to Claim 23.

26. (previously presented)A bispecific antibody comprising the peptide according to Claim 23.

Claim 27 (cancelled).

28. (previously presented) The antibody of claim 1, wherein said antibody is a

monoclonal antibody.

Claim 29 (cancelled).